Dartford and Gravesham NHS Trust to pilot ResAppDx 

RAP has signed a one year agreement with the Dartford and Gravesham National Health Service (NHS) Trust to pilot the use of ResAppDx, ResApp’s CE marked acute respiratory diagnostic test that requires only a smartphone, across its four hospitals (Darent Valley, Queen Mary’s, Erith & District, and Gravesham Community). It is expected that the pilot will commence in the third quarter of this calendar year.

The Dartford and Gravesham NHS trust provides a comprehensive range of acute services and some community services to over 500,000 people in Kent, United Kingdom. Initial use will be to assess patients who present to the Trust’s respiratory outpatient clinic before expanding use into other areas of the hospital and potentially into primary care. The local academic health science network will also be engaged as part of the trial to collaborate, support and gather data to demonstrate the efficacy of ResAppDx and how it enhances clinical and patient workflows.

Neil Perry, Director of Digital Transformation at Dartford and Gravesham NHS Trust, said “We’re really excited about the potential of ResAppDx to accelerate the digital transformation of our Trust and how we support our patients and clinicians. Our clinical team is excited about the potential of ResAppDx to accelerate and enhance the diagnosis and management of our respiratory patients. Our initial pilot will be in the Respiratory Outpatient Clinic where we will build experience, learnings, and clinical advocates before expanding into other clinical areas. We see ResAppDx as a true innovation and our team can’t wait to see the impact it brings.”

CEO and Managing Director of ResApp, Dr Tony Keating added: “This is an exciting step forward for ResAppDx in Europe, our first pilot with the NHS is an exciting milestone. We look forward to working closely with Neil and his team at Dartford & Gravesham Trust to help fully realise the benefits that ResAppDx can offer to the Trust. While the revenue from the pilot is not material at this time, we will gain significant learnings, data and experience throughout this process which will support our efforts to commercialise ResAppDx with other NHS Trusts and more broadly in Europe.” 

ResApp has completed recruitment in its COVID-19 study in India. 337 patients, including over 200 COVID-19 positive cases, across two study arms in India have been recruited. ResApp will use this data to develop a smartphone-based algorithm to instantly screen for COVID-19 and monitor disease progression.

ResApp completes COVID-19 study recruitment in India

• ResApp’s Indian COVID-19 study has completed recruitment of 337 patients, including over 200 COVID-19 positive cases
• ResApp’s US study has recruited its first patient from in-person COVID-19 testing clinic
• ResApp is using data collected in these studies to develop and train machine learning algorithms to identify COVID-19 from cough sounds recorded on a smartphone

CEO and Managing Director, Dr Tony Keating said:

“We are pleased to report that we have completed recruitment in India ahead of schedule. We are grateful to all the patients for their willingness to participate in the study, as well as the investigators and their teams for their hard work. This is an important milestone in collecting a high-quality dataset to perform the necessary development work to build, train and test machine learning algorithms capable of identifying COVID-19 from cough sounds.

“Europe is the midst of a fourth wave of COVID-19 pandemic bringing with it new lockdowns and increased hospitalisation rates. Experts agree that screening and management of COVID-19 will be an ongoing requirement for many years and ResApp is focused on the development of instant smartphonebased applications to fulfill these global needs.” 

Alodokter to launch ResAppDx in Indonesia

• Alodokter is the largest provider of telehealth services in Indonesia
• Launched in 2014, Alodokter brings high-quality medical services to more than 30 million monthly active users by providing an integrated mobile solution for patients and doctors
• The Alodokter platform connects more than 50,000 doctors and 1,500 hospitals and clinics with millions of Indonesian patients
• Alodokter to integrate ResAppDx in its online consultation platform

ResApp Health grants cough counting SDK licence to AstraZeneca Japan for asthma patient support program

• Second licensing agreement secured with AstraZeneca’s Japanese subsidiary for ResApp technology
• Extends use of cough counting from clinical research in lung cancer to a patient support program for asthma
• First time ResApp’s cough counting technology is being used outside of a clinical trial setting
• ResApp’s cough counting software development kit (SDK) to be integrated into AstraZeneca’s Asthma Monitoring App to support patients
• Cough counting SDK designed to measure frequency of patient coughs over extended periods – cough frequency can provide insight into the progression and management of respiratory disease
• Agreement is significant validation of ResApp’s technology from a leading global pharmaceutical company